Estimating the health-related quality of life burden attributable to illicit drug use in Australian adults.

IF 3.1 3区 医学 Q1 ECONOMICS
Syed Afroz Keramat, Rezwanul Rana, Addisu Shunu Beyene, Rabeya Basri, Lan Gao
{"title":"Estimating the health-related quality of life burden attributable to illicit drug use in Australian adults.","authors":"Syed Afroz Keramat, Rezwanul Rana, Addisu Shunu Beyene, Rabeya Basri, Lan Gao","doi":"10.1007/s10198-026-01948-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Illicit drug use poses a significant global public health challenge, affecting health-related quality of life (HRQoL) and contributing to disease burden. Illicit drug use is also linked to substantial adverse health and social outcomes, including mental health disorders and chronic physical morbidities. This study addresses a critical research gap by examining the association between illicit drug use and HRQoL in Australian adults.</p><p><strong>Methods: </strong>This study utilised data from two waves (wave 17 [2017] and wave 21 [2021]) of the Household, Income and Labour Dynamics in Australia (HILDA) Survey and analysed a pooled dataset comprising 29,811 person-year observations from 18,295 unique individuals. HRQoL was assessed using the Physical Component Summary (PCS), the Mental Component Summary (MCS), the Short-Form Six-Dimension utility index (SF-6D), and the eight dimensions of the SF-36 health survey. The study defined illicit drug use as self-reported use of any of the following six drug types in the past 12 months: marijuana/cannabis, methamphetamine/amphetamine, cocaine, ecstasy, hallucinogens, and any other illicit drug (e.g., heroin, GHB, ketamine, K2, and synthetics). A binary variable was created to indicate whether an individual used any of these drugs during the specified period. The random-effects generalised least squares (GLS) estimation technique was used to quantify the relationships between illicit drug use and HRQoL.</p><p><strong>Results: </strong>After adjusting for a comprehensive set of covariates, the findings revealed a significant negative association between illicit drug use and mental health. Individuals who reported illicit drug use had markedly lower MCS scores (β = -2.29, 95% CI: -2.68, -1.89) compared to non-users. Furthermore, illicit drug use was associated with a significant reduction in SF-6D utility values (β = -0.022, 95% CI: -0.026, -0.018), highlighting the adverse impact on overall HRQoL among adults. Illicit drug use was associated with reduced MCS scores and SF-6D utility values across genders and age groups, with greater reduction among young adults aged 15-29 years [(MCS = -2.30, 95% CI: -2.92, -1.68) and (SF-6D = -0.021, 95% CI: -0.027, -0.015)], and male drug users [(MCS = -2.46, 95% CI: -2.93, -1.99), and (SF-6D = -0.021, 95% CI: -0.026, -0.016)].</p><p><strong>Conclusion: </strong>The study findings confirmed that individuals who use illicit drugs experience significantly lower HRQoL than their peers. Additionally, the study provided a specific disutility value for illicit drug use, offering crucial data for future evaluations of the cost-effectiveness of drug harm reduction programs.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Health Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10198-026-01948-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Illicit drug use poses a significant global public health challenge, affecting health-related quality of life (HRQoL) and contributing to disease burden. Illicit drug use is also linked to substantial adverse health and social outcomes, including mental health disorders and chronic physical morbidities. This study addresses a critical research gap by examining the association between illicit drug use and HRQoL in Australian adults.

Methods: This study utilised data from two waves (wave 17 [2017] and wave 21 [2021]) of the Household, Income and Labour Dynamics in Australia (HILDA) Survey and analysed a pooled dataset comprising 29,811 person-year observations from 18,295 unique individuals. HRQoL was assessed using the Physical Component Summary (PCS), the Mental Component Summary (MCS), the Short-Form Six-Dimension utility index (SF-6D), and the eight dimensions of the SF-36 health survey. The study defined illicit drug use as self-reported use of any of the following six drug types in the past 12 months: marijuana/cannabis, methamphetamine/amphetamine, cocaine, ecstasy, hallucinogens, and any other illicit drug (e.g., heroin, GHB, ketamine, K2, and synthetics). A binary variable was created to indicate whether an individual used any of these drugs during the specified period. The random-effects generalised least squares (GLS) estimation technique was used to quantify the relationships between illicit drug use and HRQoL.

Results: After adjusting for a comprehensive set of covariates, the findings revealed a significant negative association between illicit drug use and mental health. Individuals who reported illicit drug use had markedly lower MCS scores (β = -2.29, 95% CI: -2.68, -1.89) compared to non-users. Furthermore, illicit drug use was associated with a significant reduction in SF-6D utility values (β = -0.022, 95% CI: -0.026, -0.018), highlighting the adverse impact on overall HRQoL among adults. Illicit drug use was associated with reduced MCS scores and SF-6D utility values across genders and age groups, with greater reduction among young adults aged 15-29 years [(MCS = -2.30, 95% CI: -2.92, -1.68) and (SF-6D = -0.021, 95% CI: -0.027, -0.015)], and male drug users [(MCS = -2.46, 95% CI: -2.93, -1.99), and (SF-6D = -0.021, 95% CI: -0.026, -0.016)].

Conclusion: The study findings confirmed that individuals who use illicit drugs experience significantly lower HRQoL than their peers. Additionally, the study provided a specific disutility value for illicit drug use, offering crucial data for future evaluations of the cost-effectiveness of drug harm reduction programs.

估计澳大利亚成年人因非法药物使用而产生的健康相关生活质量负担。
背景:非法药物使用是一项重大的全球公共卫生挑战,影响与健康有关的生活质量(HRQoL)并造成疾病负担。非法药物使用还与严重的不良健康和社会后果有关,包括精神健康障碍和慢性身体疾病。本研究通过检查澳大利亚成年人非法药物使用与HRQoL之间的关系,解决了一个关键的研究空白。方法:本研究利用了澳大利亚家庭、收入和劳动力动态(HILDA)调查的两波数据(第17波[2017]和第21波[2021]),并分析了一个汇集的数据集,其中包括来自18,295个独特个体的29,811人年观察结果。HRQoL采用身体成分摘要(PCS)、心理成分摘要(MCS)、短格式六维效用指数(SF-6D)和SF-36健康调查的八个维度进行评估。该研究将非法药物使用定义为自我报告在过去12个月内使用以下六种药物中的任何一种:大麻/大麻,甲基苯丙胺/安非他明,可卡因,摇头丸,致幻剂和任何其他非法药物(如海洛因,GHB,氯胺酮,K2和合成药物)。创建了一个二元变量来指示个人是否在指定期间使用了这些药物中的任何一种。采用随机效应广义最小二乘(GLS)估计技术量化非法药物使用与HRQoL之间的关系。结果:在对一组综合协变量进行调整后,研究结果显示非法药物使用与心理健康之间存在显著的负相关。报告非法药物使用的个体与非吸毒者相比,MCS评分明显较低(β = -2.29, 95% CI: -2.68, -1.89)。此外,非法药物使用与SF-6D效用值的显著降低相关(β = -0.022, 95% CI: -0.026, -0.018),突出了对成年人总体HRQoL的不利影响。非法药物使用与不同性别和年龄组的MCS评分和SF-6D效用值降低有关,15-29岁的年轻人[(MCS = -2.30, 95% CI: -2.92, -1.68)和(SF-6D = -0.021, 95% CI: -0.027, -0.015)]和男性吸毒者[(MCS = -2.46, 95% CI: -2.93, -1.99)和(SF-6D = -0.021, 95% CI: -0.026, -0.016)]的降低幅度更大。结论:研究结果证实,使用非法药物的个体的HRQoL明显低于同龄人。此外,该研究为非法药物使用提供了一个特定的负效用值,为未来评估减少药物危害项目的成本效益提供了关键数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
2.30%
发文量
131
期刊介绍: The European Journal of Health Economics is a journal of Health Economics and associated disciplines. The growing demand for health economics and the introduction of new guidelines in various European countries were the motivation to generate a highly scientific and at the same time practice oriented journal considering the requirements of various health care systems in Europe. The international scientific board of opinion leaders guarantees high-quality, peer-reviewed publications as well as articles for pragmatic approaches in the field of health economics. We intend to cover all aspects of health economics: • Basics of health economic approaches and methods • Pharmacoeconomics • Health Care Systems • Pricing and Reimbursement Systems • Quality-of-Life-Studies The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements. Officially cited as: Eur J Health Econ
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书